Events

News

• Avid Bioservices Welcomes Kenneth Bilenberg as New CEO

  September 15, 2025

  Tustin, CA, USA – September 15, 2025 – Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kenneth Bilenberg as its new […]

  Read more

• CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production

  August 5, 2025

  SOUTH SAN FRANCISCO, California – August 05, 2025 – Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical […]

  Read more

• GHO & Ampersand Complete Acquisition of Avid Bioservices

  February 5, 2025

  Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed GHO and Ampersand’s […]

  Read more

• Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

  February 5, 2025

  Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 — Avid Bioservices, […]

  Read more

• Avid Stockholders Approve Transaction with GHO and Ampersand

  January 30, 2025

  TUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient […]

  Read more

• Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction

  November 6, 2024

  TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high […]

  Read more

< View Older News